Oncotelic Therapeutics (OTCQB: OTLC) announced that Chief Business Officer Saran Saund will deliver the opening keynote on the second day of the 22nd Drug Discovery Strategic Summit on Oct. 22, 2026, at 9 a.m. Pacific Time in Millbrae, California. The presentation will explore partition and aggregation as an organizing principle for AI-enabled drug discovery, emphasizing how complex research questions can be divided into focused investigations and findings combined to develop testable hypotheses. The keynote matters because it positions Oncotelic at the center of a growing movement to apply artificial intelligence to the notoriously slow and expensive drug discovery process, and it offers a public platform for the company to showcase its proprietary PDAOAI platform to an audience of industry researchers and potential partners.
Saund will discuss the company’s proprietary PDAOAI platform, which indexes approximately 29 million PubMed abstracts, along with its international intellectual property strategy, planned expansion into genetic discovery and Fastbot/Membot technology designed to make AI-powered research accessible to individual investigators. The scale of that abstract index is significant: by organizing a vast body of biomedical literature into a searchable, AI-driven system, Oncotelic aims to reduce the time researchers spend sifting through data and increase the odds of generating viable hypotheses. The planned expansion into genetic discovery further signals that the company intends to broaden the platform’s applications beyond its core oncology work, potentially opening new avenues for collaboration and licensing.
The announcement also matters for Oncotelic’s broader business strategy. The company develops oncology and immunotherapy products, with a focus on cancers with substantial unmet needs and rare pediatric indications, and it develops the PDAOAI platform to support its work in drug discovery and development. By publicly detailing its AI approach at a strategic summit, Oncotelic can differentiate itself from traditional biotech peers and attract attention from investors and partners who are increasingly focused on AI-enabled research. The Fastbot/Membot technology, in particular, could democratize access to AI-powered research tools, allowing individual investigators to conduct analyses that previously required large teams and significant resources.
For investors, the keynote represents an opportunity to gauge the maturity of Oncotelic’s AI strategy and its intellectual property position. The company’s international IP strategy, if robust, could provide a competitive moat as AI drug discovery becomes more crowded. The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC. The full press release can be viewed at https://nnw.fm/O1lLk. The announcement was distributed through NetworkNewsWire, a specialized communications platform focused on financial news and content distribution, which is part of the Dynamic Brand Portfolio at IBN. NetworkNewsWire notes that it provides access to wire solutions via InvestorWire and offers corporate communications solutions to help companies reach wide audiences. Full terms of use and disclaimers are available at https://www.NetworkNewsWire.com/Disclaimer.
